Pharma Mar (OTCMKTS:PHMMF) Short Interest Up 1,430.8% in July

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 199 shares, a growth of 1,430.8% from the July 15th total of 13 shares. Based on an average daily volume of 15 shares, the days-to-cover ratio is currently 13.3 days. Currently, 0.0% of the shares of the stock are sold short.

Pharma Mar Price Performance

Shares of Pharma Mar stock opened at $87.58 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. The stock’s 50 day simple moving average is $86.86 and its 200-day simple moving average is $93.66. Pharma Mar has a 1-year low of $77.41 and a 1-year high of $110.40.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PHMMF. Chardan Capital upgraded Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. Zacks Research raised shares of Pharma Mar to a “hold” rating in a report on Monday, June 15th. Finally, BTIG Research initiated coverage on shares of Pharma Mar in a research report on Thursday, April 23rd. They issued a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.